期刊
EUROPEAN JOURNAL OF PHARMACOLOGY
卷 833, 期 -, 页码 349-356出版社
ELSEVIER
DOI: 10.1016/j.ejphar.2018.06.024
关键词
Antiarrhythmic drugs; Catheter ablation; Heart failure; Ventricular arrhythmia; Ventricular arrhythmic substrate
资金
- National Heart, Lung, and Blood Institute [1R01HL137832-01]
Heart failure (HF) is a clinical syndrome characterized by ventricular contractile dysfunction. About 50% of death in patients with HF are due to fetal ventricular arrhythmias including ventricular tachycardia and ventricular fibrillation. Understanding ventricular arrhythmic substrates and discovering effective antiarrhythmic interventions are extremely important for improving the prognosis of patients with HF and reducing its mortality. In this review, we discussed ventricular arrhythmic substrates and current clinical therapeutics for ventricular arrhythmias in HF. Base on the fact that classic antiarrhythmic drugs have the limited efficacy, side effects, and proarrhythmic potentials, we also updated some therapeutic strategies for the development of potential new antiarrhythmic interventions for patients with HF.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据